ABSTRACT: Well into the 21st century, we still triage acute myocardial infarction on the basis of the presence or absence of ST-segment elevation, a century-old technology. Meanwhile, we have learned a great deal about the pathophysiology and mechanisms of acute coronary syndromes (ACS) at the clinical, pathological, cellular, and molecular levels. Contemporary imaging studies have shed new light on the mechanisms of ACS. This review discusses these advances and their implications for clinical management of the ACS for the future. Plaque rupture has dominated our thinking about ACS pathophysiology for decades. However, current evidence suggests that a sole focus on plaque rupture vastly oversimplifies this complex collection of diseases and obscures other mechanisms that may mandate different management strategies. We propose segmenting coronary artery thrombosis caused by plaque rupture into cases with or without signs of concomitant inflammation. This distinction may have substantial therapeutic implications as direct anti-inflammatory interventions for atherosclerosis emerge. Coronary artery thrombosis caused by plaque erosion may be on the rise in an era of intense lipid lowering. Identification of patients with of ACS resulting from erosion may permit a less invasive approach to management than the current standard of care. We also now recognize ACS that occur without apparent epicardial coronary artery thrombus or stenosis. Such events may arise from spasm, microvascular disease, or other pathways. Emerging management strategies may likewise apply selectively to this category of ACS. We advocate this more mechanistic approach to the categorization of ACS to provide a framework for future tailoring, triage, and therapy for patients in a more personalized and precise manner.
W
illem Einthoven introduced electrocardiography at the dawn of the 20th century. Well into the 21st century, we still triage acute myocardial infarction on the basis of this venerable technology: ST segments up or not. Although this approach remains the appropriate evidence-based strategy today, aiming toward the future goal of more individualized therapy, can we apply a more pathophysiologically based categorization of the acute coronary syndromes (ACS)? Indeed, we have learned much about the mechanisms of ACS since we last reviewed this topic in these pages. 1, 2 Moreover, the human disease of atherosclerosis has evolved considerably in the interim. [3] [4] [5] This review aims to work toward a categorization of the ACS that reaches beyond equating all ACS with plaque rupture or fissure, guided by the latest insights into the underlying mechanisms of ACS, and points a way forward toward the eventual clinical application of these considerations.
Postmortem studies carried out in the 1980s proposed that plaque rupture (also sometimes referred to as fissure) caused most fatal myocardial infarctions. 6 These findings led to the notion of the vulnerable or high-risk plaque characterized by a large central lipid core, an abundance of inflammatory cells, a paucity of smooth muscle cells (SMCs), and a thin fibrous cap. 7 These observations spawned the widely accepted concept that instability of coronary atheromata resulted from fissuring of a thin-capped fibroatheroma caused by a weakening of its collagen structure wrought by inflammatory mechanisms. 8 This concept stimulated manifold attempts to develop methods to detect the vulnerable plaque, a quest predicated on the postulate that local interventions could preclude plaque thrombosis and possibly prevent ACS. However, attempts to identify vulnerable plaques proved disappointing because of their low predictive value. 9 Pathological studies of human coronary arteries show that plaque rupture occurs commonly in individuals without symptomatic ACS. 10 Moreover, <5% of plaques with the features of thin-capped fibroatheroma as determined by intravascular ultrasound interrogation actually cause clinical events during over 3 years of follow-up. 11 Thus, most thin-capped fibroatheroma are clinically quite stable, a realization that renders vulnerable plaque a misnomer. Indeed, plaques with thin-capped fibroatheroma morphology as assessed by radiofrequency backscatter data from intravascular ultrasound (virtual histology) commonly convert to an apparently more stable character during a 1-year follow-up period. 12 Such evolution in plaques may reflect mutability during the natural history of human atherosclerosis but could also reflect adherence of many of these patients to a contemporary secondary prevention regimen, including smoking cessation, statins, and agents that target the renin-angiotensin axis.
Moreover, although we have witnessed wide acceptance of the formerly controversial concept that inflammation contributes to atherogenesis, 13 inflammation may not drive all transitions from stable atherosclerosis to acute thrombotic events. In a large study, about half of ACS occurred in the presence of normal levels of C-reactive protein (CRP), a marker of inflammation. 14 Another recent study using optical coherence tomography (OCT) demonstrated that among patients with ACS and plaque rupture, two thirds of patients had imaging evidence of inflammatory cell infiltration in the region of the ruptured fibrous cap but one third did not and the latter had lower levels of CRP. 15 In addition, plaque erosion causes up to a third of ACS in the current era. 16, 17 Finally, about one fifth of ACS occur in the apparent absence of coronary thrombosis, suggesting that functional alterations beyond thrombus formation can contribute to ACS pathogenesis. 18, 19 The ensemble of postmortem studies and in vivo studies using intravascular imaging point to 4 pathological pathways to ACS. Although these mechanisms may overlap and coexist in some patients, we present them separately for heuristic simplicity: plaque rupture with systemic inflammation, plaque rupture without systemic inflammation, plaque erosion, and plaque without thrombus (Figure 1) . 20 This review considers the causes of these 4 predominant pathways to ACS. To strive for a more precision approach, we explore the therapeutic implications of these distinct mechanisms that provoke ACS. Moreover, we advocate the future goal to move beyond triage of therapy based merely on electrocardiographic current of injury by harnessing the recent advances in arterial biology and human studies that shed new mechanistic light on ACS pathogenesis. Further improvements in the appropriate deployment of technologies and in outcomes should evolve from a more mechanistically based classification of ACS.
PLAQUE RUPTURE WITH SYSTEMIC INFLAMMATION Mechanisms
Several studies have implicated systemic inflammation in ACS as assessed by the biomarker CRP ( Figure 1A ). 21 Laboratory studies and observations on human plaques point to inflammatory mechanisms as key regulators of the fragility of the fibrous cap and of the thrombogenic potential of the lipid core ( Figure 2 lation, activation of zymogen precursors, and balance with endogenous inhibitors such as the tissue inhibitors of matrix metalloproteinases or the cystatins. Thus, increased amounts of activated proteinases or reduced levels of their corresponding inhibitors can enhance breakdown of the extracellular matrix of plaque. 22 Adaptive immunity also appears altered in coronary plaque instability. 23 Patients with ACS have an increased population of particularly proinflammatory CD4 + T cells characterized by low cell surface expression of CD28, a costimulatory molecule critically involved in determining the outcome of antigen recognition by T cells. 24 25, 26 T regs normally help to maintain homeostasis of cells involved in adaptive immunity, including antigenpresenting cells and effector T cells. T regs mediate these modulatory effects by contact-dependent suppression or by releasing anti-inflammatory cytokines such IL-10 or transforming growth factor-β1. 27 Patients with ACS have a reduced number and suppressive function of circulating T regs compared with patients with stable angina and healthy control subjects. 28 The molecular mechanisms responsible for the T-cell dysregulation in ACS remain largely unknown. Recent work highlights the importance of the strength of the stimulation of the T-cell receptor for antigen in the differentiation of helper T-cell subsets. The altered activity observed in ACS of proteins involved in the regulation of upstream T-cell receptor for antigen signaling such as CD31 and protein tyrosine phosphatase N22 may modulate T-cell functions. 29 
Therapeutic Implications
Several anti-inflammatory treatments might provide benefit in this setting. Colchicine, a time-honored anti-inflammatory drug, reduced major cardiovascular events in a medium-sized, unblinded randomized study in patients with stable ischemic heart disease. 31 Two trials underway are evaluating colchicine treatment in patients with coronary artery disease, although not in the acute phase. 32 A phase III trial is testing the potential beneficial effects of low-dose methotrexate in patients after myocardial infarction or with coronary artery disease and diabetes mellitus or elements of the metabolic syndrome. 33 Targeting proinflammatory cytokines offers another approach. Because of the potentially detrimental effects on cardiovascular risk profile or the lack of compelling evidence of benefit in experimental atherosclerosis, monoclonal antibodies that neutralize tumor necrosis factor-α, interferon-γ, or IL-17 may not prove appropriate for treating atherosclerosis. In a small (n=182) phase II study, the IL-1 receptor antagonist anakinra reduced the area under the curve of highsensitivity CRP in patients in the 7 days after presentation with ACS. 34 A large (n>10 000) phase III trial with clinical end points that tested a fully humanized anti-IL-1β monoclonal antibody, canakinumab, in patients with previous myocardial infarction and CRP levels >2 mg/L showed a significant 15% reduction in the primary endpoint of MI, stroke, or death, and a 17% fall in a secondary endpoint that included urgent revascularization. Indeed, revascularization procedures declined 30% in the group that received the interleukin-1β neutralizing antibody canakinumab 150mg subcutaneously every 3 months. This intervention trial substantiates the causal contribution of inflammation to atherosclerotic events. [35] [36] [37] T-cell activation signaling offers possible targets. A synthetic CD31-derived peptide can suppresses immunity in vivo by restoring an inhibitory pathway to a CD31-negative T-cell subset. 38 Moreover, the development of a novel series of inhibitors of the phosphatase protein tyrosine phosphatase N22 might contribute to a better understanding of its role in immune dysregulation in patients with ACS. 39 Therapeutic strategies that target T reg include administration of low doses of IL-2 and infusion of autologous T regs that have undergone differentiation and expansion in vitro. 40 Various vaccination strategies also can limit experimental atherogenesis and may act by augmenting the activity of T reg . 41 
PLAQUE RUPTURE WITHOUT SYSTEMIC INFLAMMATION Mechanisms
When plaque rupture occurs in the absence of systemic inflammatory activation, other mechanisms may contribute to pathogenesis, including extreme emotional disturbance ranging from external events of short duration such as earthquakes and a beloved team's loss of a football (soccer) match to acute manifestations of more long-term emotional disturbances ( Figure 1B ). Intense physical exertion and local mechanical stress at the level of the artery wall, either increased circumferential stress or reduced shear stress, may also predispose to plaque rupture. 42 In addition, subclinical inflammation in the microenvironment of the culprit stenosis might compound the chain of events leading to coronary instability, although the triggers for and effectors of such local inflammation may differ from those that operate in patients with systemic inflammation. 43 Although many studies have clarified the molecular mechanisms leading to coronary instability in individuals with systemic inflammation (eg, gauged by CRP elevations), patients without systemic inflammation have undergone less extensive investigation. The precise causes of instability remain poorly understood, providing a strong stimulus for further research.
The possible relationship between psychological stress and plaque rupture may relate to sympathetic nervous system activation and catecholamine release associated with an increase in heart rate, blood pressure, and coronary vasoconstriction favoring plaque disruption and platelet activation, hypercoagulability, and intense coronary microvascular constriction. 44 Moreover, β 3 -adrenergic stimulation can stimulate release from the bone marrow of proinflammatory monocytes that can home to experimental atheromata and amplify local inflammation. 45 Although physical or emotional stress per se may not suffice to cause coronary thrombosis, it might trigger instability in plaques already predisposed to provoke events. Local changes in the equilibrium between esterified and free cholesterol might promote plaque rupture 47 (Figure 3) . Cholesterol crystal formation in the lipid core could heighten the risk of plaque rupture and thrombosis and can coactivate the inflammasome, an intracellular multimeric complex that generates active IL-1β and IL-18. 48 OCT has colocalized cholesterol crystals in human coronary arteries with thin-capped plaques. 49 The development of micro-OCT with a 2-μm resolution may shed new light on this potential mechanism of instability by assessing its occurrence in vivo. 50 Cholesterol crystals might also theoretically resist plaque rupture by increasing the stiffness of the lipid pool, although this mechanism probably contributes little to plaque stability. 51 The role of calcium mineral as a causal factor in ACS remains controversial. Large collections of calcified tissue do not augment the biomechanical instability of plaques or associate with lesions that provoke ACS. 52, 53 Small foci of calcification within the atherosclerotic intima, some causing spotty calcification visible on computed tomography, can also introduce biomechanical inhomogeneities that can favor plaque destabilization.
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Therapeutic Implications
Because it is difficult to limit environmental, physical, or emotional triggers, the altered plaque characteristics produced by intensive lipid-lowering treatment might protect against this form of plaque destabilization. 56 In particular, statins and ezetimibe may interfere with cholesterol crystal formation. 57, 58 Cyclodextrin can solubilize cholesterol, limits experimental atherogenesis, and thus might provide a pharmacological approach to combatting cholesterol crystal accumulation in plaques. 59 Enhancement of cholesterol efflux might promote plaque stabilization, but strategies to enhance this process by manipulation of high-density lipoprotein concentrations or by administration of apolipoprotein A-1 have generally failed to confer clinical benefit. 60 A large outcome trial with anacetrapib produced a modest event reduction, but since this agent not only raises high-density lipoprotein but also lowers low-density lipoprotein renders it difficult to attribute event reduction to raising high-density lipoprotein. 61 In addition, the inhibition of cholesteryl ester hydrolase, an enzyme that converts cholesteryl esters to free cholesterol, might prevent cholesterol crystallization. Inhibition of acetyl-CoA acetyltransferase-1, which in contrast promotes cholesterol crystallization, increased atheroma volume and major cardiovascular events.
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PLAQUE EROSION Mechanisms
Current evidence suggests that mechanisms of plaque disruption distinct from macrophage-driven rupture of the fibrous cap of plaque can commonly cause ACS. 63 The mechanism of plaque thrombosis described by pathologists as superficial erosion appears not to involve inflammation mediated by macrophages, as in the case of fibrous cap fracture ( Figure 1C ). Superficial erosion complicates lesions with a distinct epidemiology and morphology and involves pathophysiological mechanisms that differ from rupture of the fibrous cap. Indeed, neutrophil activation seems to play a pivotal role in thrombosis due to plaque erosion. 4 Patients who presented with ACS associated with plaque erosion defined by OCT had higher systemic myeloperoxidase levels compared with patients with plaque rupture. Moreover, in postmortem coronary artery specimens, luminal thrombi superimposed on eroded plaques contain many more myeloperoxidase-positive cells than thrombi associated with ruptured plaques 64 ( Figure 4 ). Autopsy studies suggest that fatal plaque erosion associates more commonly with hypertriglyceridemia, diabetes mellitus, female sex, and old age. 65 The morphology of lesions that produce thrombosis caused by superficial erosion differs radically from the features associated with fibrous cap rupture. Superficially eroded lesions contain few macrophages or T lymphocytes, inflammatory cells considered pathogenic in plaque rupture. Rather than depleted collagen, the lesions associated with superficial erosion contain abundant proteoglycan and glycosaminoglycans. Instead of a paucity of SMCs, eroded lesions can contain abundant arterial SMCs. Plaques complicated by fibrous cap fracture typically harbor large necrotic, lipid-rich cores. In contrast, the more fibrous lesions associated with superficial erosion generally lack prominent central lipid cores. 66 A loss of intimal endothelial cells defines lesions that provoke thrombosis by the mechanism denoted as superficial erosion.
Recent work has implicated engagement of the innate immune receptor Toll-like receptor 2 in promoting the susceptibility of endothelial cells to apoptotic stimuli. Hyaluronic acid, a prominent constituent of the extracellular matrix of eroded lesions, could serve as an endogenous ligand of Toll-like receptor 2, implicated in promoting endothelial cell apoptosis. 67 Experiments that have evaluated gain and loss of Toll-like receptor 2 function in mice support these observations. 68 Indeed, hyaluronan and its receptor, CD44, colocalize along the plaque/thrombus interface in eroded plaque but not in ruptured or stable plaque. 69 Accumulation of hyaluronan and expression of CD44 along the plaque/thrombus interface of eroded plaques may promote de-endothelization, resulting in CD44-dependent platelet adhesion and subsequent thrombus formation, mediated in part by a direct action of hyaluronan on fibrin polymerization. 70, 71 We have hypothesized that thrombosis caused by superficial erosion occurs in 2 phases. The first hit, mediated, for example, by Toll-like receptor 2, would jeopardize endothelial viability or adherence, leading to a breach in the integrity of the endothelial monolayer overlying the atherosclerotic plaque. The denuded patch on the intimal surface would then attract platelets that could undergo activation by contact with collagen and other components of the arterial extracellular matrix usually protected from the blood compartment by the endothelial lining of the intima. The second hit, mediated by the release of granular contents from activated platelets and the local production of chemoattractants for polymorphonuclear leukocytes, would beckon these granulocytes to join the platelets at local sites of endothelial denudation. In turn, the activation of polymorphonuclear leukocytes could generate structures known as neutrophil extracellular traps, made up of strands of unwound DNA released by the dying granulocytes. 72 This uncoiled DNA becomes decorated with proteases, tissue factor, and pro-oxidant enzymes that could propagate local amplification of an innate immune response, thrombin activation, and fibrin generation and entrap further platelets and fibrin strands in an evolving thrombus. 51 This hypothetical scenario posits a mechanism of thrombosis that is independent of the chronic inflammatory cells typically implicated in fibrous cap rupture: macrophages and T lymphocytes. Rather, this schema implicates different arms of innate immunity in thrombus initiation, propagation, and stabilization. These mechanistic differences with fibrous cap fracture have potential therapeutic implications.
Therapeutic Implications
Because statins alter the lipid profile primarily by lowering low-density lipoprotein rather than triglycerides, therapies that address triglyceride-rich lipoproteins may address the residual risk of events resulting from erosion that persists in the statin era more effectively than more intense low-density lipoprotein-lowering therapies. 73 Moreover, therapies that destabilize neutrophil extracellular traps such as deoxyribonuclease administration might limit the propagation of thrombi resulting from superficial erosion. 74 Receptors such as CD44 expressed by neutrophils may bind hyaluronan and glycosaminoglycan enriched in plaques complicated by erosion and furnish a potential therapeutic target. 75 Jia et al 76 recently reported a series of patients with ACS with OCT-defined erosion and treated with anticoagulant/antiplatelet therapy rather that mechanical revascularization. About 80% of the patients showed a >50% reduction of thrombus volume after 1 month. More than a third of patients lacked detectable thrombus after 1 month. This study suggests that pharmacological rather than interventional treatment can effectively manage ACS caused by superficial erosion, a proposition that merits and requires rigorous testing in outcome trials.
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PLAQUE WITHOUT THROMBUS Mechanisms
In patients with ACS without plaque thrombus, a functional alteration of coronary circulation likely causes Stimuli such as disturbed flow or engagement of innate immune receptors such as Toll-like receptor-2 (TLR2) can activate the endothelial cells that line the arterial intima. These cells can undergo cell death, eg, by apoptosis, depicted by the cell with the interrupted membrane and pyknotic nucleus. Injured or dying endothelial cells can desquamate, uncovering the basement membrane. Neutrophils attracted by chemokines produced by activated endothelial cells can congregate on the denuded intima and can in turn degranulate and die, releasing neutrophil extracellular traps (NETs). These strands of extruded DNA can bind the contents of the neutrophil granules and other proteins, eg, myeloperoxidase or tissue factor. The NETs can constitute a solid-state reactor that generates oxidants such as hypochlorous acid and stimulates coagulation locally. Platelets interacting with the basement membrane can activate, release their granular contents, including chemokines that can recruit further leukocytes, and form the nidus of a white thrombus.
acute ischemia involving large epicardial coronary arteries or the coronary microcirculation ( Figure 1D ). Epicardial coronary vasospasm may occur in patients in whom coronary angiography does not demonstrate an obstructive atherosclerotic plaque. 78 In the CASPAR study (Coronary Artery Spasm in Patients With Acute Coronary Syndrome), coronary angiography failed to show culprit lesions in ≈30% of patients with suspected ACS. 79 Intracoronary acetylcholine administration elicited coronary spasm in nearly 50% of these patients. Similar findings pertained to a Japanese population. 80 Coronary artery spasm also may cause coronary instability in patients with obstructive atherosclerosis. Indeed, a classic study by Bertrand et al 81 found that ergonovine induced spasm in 20% of patients with recent myocardial infarction and in 40% of patients with unstable angina. In a more recent study, acetylcholine induced spasm in 20% of white patients and in 60% of patients with myocardial infarction within the previous 14 days. 82 Japanese people have a higher prevalence of coronary spasm than whites for unknown reasons. Microvascular spasm also can cause myocardial ischemia. 83 This mechanism likely operates in patients with Takotsubo cardiomyopathy, 84 which frequently occurs in the absence of obstructive atherosclerosis, although ≈15% of these patients exhibit concomitant obstructive atherosclerosis. 85 Microvascular spasm can also contribute to ischemia in the face of angiographically normalappearing epicardial coronary arteries. Microvascular ischemia often manifests as angina pectoris but can also cause non-ST-segment-elevation ACS as defined by electrocardiographic alterations and biomarker evidence of myocyte injury. 86 Coronary spasm can also contribute to plaque instability by causing endothelial damage, as shown in an infarction-prone strain of the Watanabe heritable hyperlipidemic rabbit. 44 Either macrovascular or microvascular spasm can result from impaired vasodilatation or from vasoconstrictor stimuli acting on hyperreactive vascular SMCs ( Figure 5) . 87, 88 Shimokawa et al 89 demonstrated SMC hyperreactivity in a coronary segment in pigs after adventitial exposure of a coronary segment to an inflammatory stimulus (IL-1β). Subsequent experimental and clinical data suggested that an increase in Rhokinase activity was a major mechanism of SMC hyperreactivity. [90] [91] [92] Perivascular fibrosis in the coronary microvasculature can contribute to myocardial ischemia. 93 This observation highlights the potential contribution of fixed structural changes in coronary arterioles beyond impaired endothelial vasodilator function as a contributor to myocardial ischemia in the absence of obstructive disease of the epicardial coronary arteries.
Therapeutic Implications
Several vasoconstrictor substances implicated as triggers of epicardial coronary spasm may cause ischemia in the same patient under different conditions. 94 Accordingly, the vasoactive substances themselves may not respond to therapeutic targeting. The current treatment of epicardial spasm uses nonspecific vasodilators such as long-acting nitrates and calcium channel blockers. 95 Nitrates and calcium channel antagonists may alleviate ischemia caused by vasospasm. However, we need to identify the molecular alterations responsible for SMC hyperreactivity because many patients do not respond satisfactorily to standard doses of vasodilators. 96 Knowledge of the postreceptor mechanisms responsible for SMC hyperreactivity and epicardial coronary spasm might enable the development of new therapeutic options for patients who present poor clinical response to nonspecific vasodilator therapy. Fasudil, a Rho kinase inhibitor, reduces the rate of coronary spasm episodes in patients with vasospastic angina. 97 Similarly, further efforts are warranted to unravel the molecular mechanisms responsible for coronary microvascular dysfunction in Takotsubo cardiomyopathy and in ischemia with normal coronary arteries. 20 The observation that Takotsubo cardiomyopathy may have worse outcomes than previously considered and the challenges of managing patients with episodic ischemia caused by microvascular dysfunction render this quest urgent. 85 Preventing or reversing perivascular fibrosis in the coronary arterial microvasculature represents another novel target beyond traditional antiatherosclerotic therapies.
CONCLUSIONS AND PERSPECTIVES
A dichotomous approach based on the ECG has traditionally dominated our clinical management of ACS: ST-segment-myocardial infarction versus non-STsegment-myocardial infarction. Our thinking concerning the pathophysiological bases of the ACS has also evolved separately and, in parallel, has been dominated by the concept of the vulnerable plaque as a substrate for fibrous cap rupture or of a minority mechanism: superficial erosion. We and others have championed and explored the role of inflammation as a pathway to the ACS.
However, we now have a greater appreciation that not all cases of ACS fit this mold. To move forward, we need to remain vigilant not to cling to our cherished notions and to remain open to shifts in the nature of the diseases we treat and to new vistas opened by scientific advances. As discussed here, we need to consider more deeply in the current era arterial spasm, rupture without inflammation, and distinct aspects of innate immunity or dyslipidemia as instigators of plaque erosion. The complexity of clinical ACS surpasses our traditional categorization of this condition. We should evolve beyond the current constrained concepts by expanding our understanding.
We have achieved considerable mastery of plaque rupture with inflammation from a mechanistic and therapeutic viewpoint. Control of traditional risk factors such as hypercholesterolemia, hypertension, and smoking addresses the pathophysiology of this mechanism of ACS. The other categories that we discuss here may account for an increasing proportion of ACS, now that we are addressing more effectively the traditional risk factors. 5 We should remain open to the possibility, even likelihood, that tailored therapeutic approaches may apply to the prevention and treatment of the less well-recognized pathways to acute myocardial ischemia discussed here.
We must aim to link the clinical presentation of ACS more tightly to pathophysiological mechanisms. More than a century after the introduction of ECG, we still triage our patients with ACS on the basis of this mature technology. To move forward in the management of ACS, we should strive for a more personalized approach to therapy based on criteria more tightly linked to the diverse pathophysiological mechanisms than ECG repolarization abnormalities. We need to develop and validate soluble and imaging biomarkers that reflect the underlying mechanism that yields acute ischemia. Point-of-care assessment of such biomarkers would help render their use clinically practical in the triage of patients who present with ACS, with the goal of sparing some the need for urgent invasive diagnostic or therapeutic measures. 18, 67, 98 We then need rigorous clinical evaluation of targeted therapies guided by a more precise pathophysiological classification of ACS that reaches beyond our current dichotomous approach based on the ECG. If these ventures succeed, we may one day look back on today's treatment of ACS as oversimplified and rather primitive. We should strive as a community not to be satisfied with our current approach to ACS management but reach to realize the promise of a more personalized precision deployment of treatment strategies, including new ones based on greater mechanistic understanding of the diverse underlying causes of acute myocardial ischemia.
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